{"id":50375,"date":"2022-11-02T13:02:32","date_gmt":"2022-11-02T12:02:32","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/omnicell-announces-financial-results-for-third-quarter-2022\/"},"modified":"2022-11-02T13:02:32","modified_gmt":"2022-11-02T12:02:32","slug":"omnicell-announces-financial-results-for-third-quarter-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/omnicell-announces-financial-results-for-third-quarter-2022\/","title":{"rendered":"Omnicell Announces Financial Results for Third Quarter 2022"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<i>GAAP and non-GAAP revenues of $348 million<\/i>\n<\/p>\n<p class=\"bwalignc\">\n<i>G<\/i><i>AAP net income per diluted share of $0.37<\/i>\n<\/p>\n<p class=\"bwalignc\">\n<i>Non-GAAP net income per diluted share of $1.00<\/i>\n<\/p>\n<p>SANTA CLARA, Calif.&#8211;(BUSINESS WIRE)&#8211;Omnicell, Inc. (NASDAQ:OMCL) (\u201cOmnicell,\u201d \u201cwe,\u201d \u201cour,\u201d \u201cus,\u201d \u201cmanagement,\u201d or the \u201cCompany\u201d), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its third quarter ended September 30, 2022 and updated 2022 guidance.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221102005381\/en\/770780\/5\/01_omnicell_lockup_horizontal_green_rgb.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221102005381\/en\/770780\/21\/01_omnicell_lockup_horizontal_green_rgb.jpg\"><\/a><\/p>\n<p>\nRandall Lipps, Chairman, President, Chief Executive Officer, and Founder of Omnicell, said, \u201cIn the third quarter, we experienced headwinds in our point of care products, driven by health system capital budget freezes and delays and ongoing customer labor availability challenges. These factors weighed on our results and drove our updated outlook for the full year. We intend to take steps to adjust our cost structure that are designed to address these headwinds, while remaining focused on investing in our innovation roadmap, and we will continue to be nimble in navigating this dynamic macro-economic environment. We continue to advance our strategy to transform the pharmacy care delivery model and provide what we believe are mission critical medication management solutions to our customers. Importantly, we believe our shift to an \u201cas a service model\u201d is working as demand for our Advanced Services including our EnlivenHealth Retail SaaS solutions remains strong. In addition, we had a record number of Central Pharmacy Dispensing Systems installed during the third quarter. While we anticipate operating against a challenging backdrop near-term, we continue to be confident in our strategy and our ability to drive long-term sustainable value for all of our stakeholders.\u201d\n<\/p>\n<p>\n<b>GAAP Results<\/b>\n<\/p>\n<p>\nTotal GAAP revenues for the third quarter of 2022 were $348 million, up $52 million, or 17%, from the third quarter of 2021. The increase in GAAP revenues reflects continued strong demand for Omnicell\u2019s mission critical medication management solutions, as well as the contribution of revenues from recent acquisitions.\n<\/p>\n<p>\nGAAP net income for the third quarter of 2022 was $17 million, or $0.37 per diluted share. This compares to GAAP net income of $29 million, or $0.61 per diluted share, for the third quarter of 2021.\n<\/p>\n<p>\n<b>Non-GAAP Results<\/b>\n<\/p>\n<p>\nTotal non-GAAP revenues for the third quarter of 2022 were $348 million, up $52 million, or 17%, from the third quarter of 2021. The increase in non-GAAP revenues reflects strong demand for Omnicell\u2019s mission critical medication management solutions, as well as the contribution of revenues from recent acquisitions.\n<\/p>\n<p>\nNon-GAAP net income for the third quarter of 2022 was $45 million, or $1.00 per diluted share. This compares to non-GAAP net income of $50 million, or $1.08 per diluted share, for the third quarter of 2021.\n<\/p>\n<p>\nNon-GAAP EBITDA for the third quarter of 2022 was $61 million. This compares to non-GAAP EBITDA of $66 million for the third quarter of 2021.\n<\/p>\n<p>\n<b>Balance Sheet<\/b>\n<\/p>\n<p>\nAs of September 30, 2022, Omnicell\u2019s balance sheet reflected cash and cash equivalents of $266 million, total debt (net of unamortized debt issuance costs) of $566 million, and total assets of $2.18 billion. Cash flows provided by operating activities in the third quarter of 2022 totaled $21 million. This compares to cash flows provided by operating activities totaling $43 million in the third quarter of 2021.\n<\/p>\n<p>\nAs of September 30, 2022, the Company had $500 million of availability under its revolving credit facility.\n<\/p>\n<p>\n<b>Business Highlights<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nRobust demand for Advanced Services during the third quarter\n<\/li>\n<li>\nAdded two new long-term sole source customers, bringing total number of long-term sole source customers to 152 of the top 300 U.S. Health Systems<sup>1<\/sup>\n<\/li>\n<li>\nIlluminate attended by key customers, with launch of Specialty Pharmacy Services offering\n<\/li>\n<\/ul>\n<p>\n<b>2022 Guidance<\/b>\n<\/p>\n<p>\nFor the full year 2022, the Company now expects product bookings to be between $950 million and $1.050 billion. The Company expects full year 2022 total GAAP and non-GAAP revenues to be between $1.284 billion and $1.294 billion. Omnicell now expects full year 2022 GAAP and non-GAAP product revenues to be between $889 million and $894 million, and full year 2022 GAAP and non-GAAP service revenues to be between $395 million and $400 million. The Company now expects full year 2022 non-GAAP EBITDA to be between $177 million and $183 million. The Company expects full year 2022 non-GAAP earnings to be between $2.73 and $2.83 per share.\n<\/p>\n<p>\nFor the fourth quarter of 2022, the Company expects total GAAP and non-GAAP revenues to be between $285 million and $295 million. The Company expects fourth quarter 2022 GAAP and non-GAAP product revenues to be between $183 million and $188 million, and fourth quarter 2022 GAAP and non-GAAP service revenues to be between $102 million and $107 million. The Company expects fourth quarter 2022 non-GAAP EBITDA to be between $10 million and $16 million. The Company expects fourth quarter 2022 non-GAAP earnings to be between $0.05 and $0.15 per share.\n<\/p>\n<p>\nThe Company\u2019s fourth quarter and full year 2022 guidance has been adjusted to include the anticipated contributions and integration costs of recent acquisitions, as well as the anticipated effects of the current inflationary environment and expected impact of current macro-economic headwinds.\n<\/p>\n<p>\nThe table below summarizes Omnicell\u2019s 2022 guidance outlined above.\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignb bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwtopsingle bwsinglebottom bwleftsingle bwpadl0 bwwidth29 bwnowrap\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Q4\u201922<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth34 bwnowrap\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>FY 2022<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwsinglebottom bwleftsingle bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Product Bookings<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwleftsingle bwpadl0 bwwidth29\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nNot provided\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth34\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$950 million &#8211; $1.050 billion\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwsinglebottom bwleftsingle bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Total GAAP and Non-GAAP Revenues<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwleftsingle bwpadl0 bwwidth29\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$285 million &#8211; $295 million\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth34\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$1.284 billion &#8211; $1.294 billion\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwsinglebottom bwleftsingle bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>GAAP and Non-GAAP Product Revenues<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwleftsingle bwpadl0 bwwidth29\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$183 million &#8211; $188 million\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth34\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$889 million &#8211; $894 million\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwsinglebottom bwleftsingle bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>GAAP and Non-GAAP Service Revenues<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwleftsingle bwpadl0 bwwidth29\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$102 million &#8211; $107 million\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth34\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$395 million &#8211; $400 million\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwsinglebottom bwleftsingle bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Non-GAAP EBITDA<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwleftsingle bwpadl0 bwwidth29\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$10 million &#8211; $16 million\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth34\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$177 million &#8211; $183 million\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwsinglebottom bwleftsingle bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Non-GAAP Earnings Per Share<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwleftsingle bwpadl0 bwwidth29\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$0.05 &#8211; $0.15\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth34\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n$2.73 &#8211; $2.83\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\nThe Company does not provide guidance for GAAP net income or GAAP earnings per share, nor a reconciliation of these forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures on a forward-looking basis because it is unable to predict certain items contained in the GAAP measures without unreasonable efforts. These forward-looking non-GAAP financial measures do not include certain items, which may be significant, including, but not limited to, unusual gains and losses, costs associated with future restructurings, acquisition-related expenses, and certain tax and litigation outcomes.\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<sup>________________________________<\/sup>\n<\/p>\n<p class=\"bwcellpmargin\">\n<sup>1<\/sup> As of 11\/2\/2022 and as defined by Definitive Healthcare\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>Omnicell Conference Call Information<\/b>\n<\/p>\n<p>\nOmnicell will hold a conference call today, Wednesday, November 2, 2022 at 8:30 a.m. ET to discuss its third quarter 2022 financial results. The conference call can be accessed by dialing 1-888-550-5424 within the U.S. or 1-646-960-0819 for all other locations. The Conference ID # is 9581556. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell\u2019s website at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fir.omnicell.com%2Fevents-and-presentations%2F&amp;esheet=52958393&amp;newsitemid=20221102005381&amp;lan=en-US&amp;anchor=http%3A%2F%2Fir.omnicell.com%2Fevents-and-presentations%2F&amp;index=1&amp;md5=77c39cf8322e42c5bafe5f9d00b987eb\" rel=\"nofollow noopener\" shape=\"rect\">http:\/\/ir.omnicell.com\/events-and-presentations\/<\/a>.\n<\/p>\n<p>\n<b>About Omnicell<\/b>\n<\/p>\n<p>\nSince 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the industry vision of the Autonomous Pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings.\n<\/p>\n<p>\nFacilities worldwide use our automation and analytics solutions to increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. Institutional and retail pharmacies across North America, the United Kingdom, Germany, and Australia leverage our innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions.\n<\/p>\n<p>\nTo learn more, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.omnicell.com&amp;esheet=52958393&amp;newsitemid=20221102005381&amp;lan=en-US&amp;anchor=www.omnicell.com&amp;index=2&amp;md5=c8f31233bd12d7c3f2d359736fb9e3ad\" rel=\"nofollow noopener\" shape=\"rect\">www.omnicell.com<\/a>. From time to time, Omnicell may use the Company\u2019s investor relations website and other online social media channels, including its Twitter handle <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.twitter.com%2Fomnicell&amp;esheet=52958393&amp;newsitemid=20221102005381&amp;lan=en-US&amp;anchor=www.twitter.com%2Fomnicell&amp;index=3&amp;md5=1a5a4ba7bda1ba49af86d7e189dc0346\" rel=\"nofollow noopener\" shape=\"rect\">www.twitter.com\/omnicell<\/a>, LinkedIn page <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fomnicell&amp;esheet=52958393&amp;newsitemid=20221102005381&amp;lan=en-US&amp;anchor=www.linkedin.com%2Fcompany%2Fomnicell&amp;index=4&amp;md5=0d510815b4dc79881390dc21d2948a2b\" rel=\"nofollow noopener\" shape=\"rect\">www.linkedin.com\/company\/omnicell<\/a>, and Facebook page <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2Fomnicellinc&amp;esheet=52958393&amp;newsitemid=20221102005381&amp;lan=en-US&amp;anchor=www.facebook.com%2Fomnicellinc&amp;index=5&amp;md5=0f36b9a6647e5fa6a8e98fce8305ab76\" rel=\"nofollow noopener\" shape=\"rect\">www.facebook.com\/omnicellinc<\/a>, to disclose material non-public information and comply with its disclosure obligations under Regulation Fair Disclosure (\u201cReg FD\u201d).\n<\/p>\n<p>\nOMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries.\n<\/p>\n<p>\n<b>Forward-Looking Statements<\/b>\n<\/p>\n<p>\nTo the extent any statements contained in this press release deal with information that is not historical, these statements are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, statements including the words \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cforecast,\u201d \u201cguidance,\u201d \u201coutlook,\u201d \u201cgoals,\u201d \u201ctarget,\u201d \u201cestimate,\u201d \u201cseek,\u201d \u201cpredict,\u201d \u201cproject,\u201d and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell\u2019s control. Such statements include, but are not limited to, Omnicell\u2019s projected bookings, GAAP and non-GAAP revenues, including GAAP and non-GAAP product and service revenues, respectively, non-GAAP EBITDA, and non-GAAP earnings per share; expectations regarding transitioning to selling more products and services on a subscription basis; and statements about Omnicell\u2019s strategy, plans, objectives, goals, vision, planned investments, and cost containment measures. Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, (i) risks related to the ongoing COVID-19 pandemic (including new variants of the virus), (ii) Omnicell\u2019s ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (iii) continued and increased competition from current and future competitors in the medication management automation solutions market and the medication adherence solutions market, (iv) unfavorable general economic and market conditions, including the impact and duration of inflationary pressures, (v) reduction in demand in the capital equipment market or reduction in the demand for or adoption of our solutions, systems, or services, (vi) delays in installations of our medication management solutions or our more complex medication packaging systems, (vii) changes to the 340B Program, (viii) Omnicell\u2019s substantial debt, which could impair its financial flexibility and access to capital, (ix) risks related to Omnicell\u2019s investments in new business strategies or initiatives, including its transition to selling more products and services on a subscription basis, and its ability to acquire companies, businesses, or technologies and successfully integrate such acquisitions, (x) risks presented by government regulations, legislative changes, fraud and anti-kickback statues, products liability claims, the outcome of legal proceedings, and other legal obligations related to healthcare, privacy, data protection, and information security, including any potential governmental investigations and enforcement actions, litigation, fines and penalties, exposure to indemnification obligations or other liabilities, and adverse publicity as a result of the previously disclosed ransomware incident, (xi) any disruption in Omnicell\u2019s information technology systems and breaches of data security or cyber-attacks on its systems or solutions, including the previously disclosed ransomware incident and any potential adverse legal, reputational, and financial effects that may result from it and\/or additional cybersecurity incidents, as well as the effectiveness of business continuity plans during any future cybersecurity incidents, (xii) risks associated with operating in foreign countries, (xiii) Omnicell\u2019s ability to recruit and retain skilled and motivated personnel, (xiv) Omnicell\u2019s ability to protect its intellectual property, (xv) Omnicell\u2019s ability to meet the demands of, or maintain relationships with, its institutional, retail, and specialty pharmacy customers, (xvi) risks related to the availability and sources of raw materials and components or price fluctuations, shortages, or interruptions of supply, (xvii) Omnicell\u2019s dependence on a limited number of suppliers for certain components, equipment, and raw materials, as well as technologies provided by third-party vendors, and (xviii) other risks and uncertainties further described in the \u201cRisk Factors\u201d section of Omnicell\u2019s most recent Annual Report on Form 10-K, as well as in Omnicell\u2019s other reports filed with or furnished to the United States Securities and Exchange Commission (\u201cSEC\u201d), available at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=52958393&amp;newsitemid=20221102005381&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=a47f54f1b94cbbac88cdf0a51972c4bb\" rel=\"nofollow noopener\" shape=\"rect\">www.sec.gov<\/a>. Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.\n<\/p>\n<p>\n<b>Use of Non-GAAP Financial Information<\/b>\n<\/p>\n<p>\nThis press release contains financial measures that are not calculated in accordance with U.S. Generally Accepted Accounting Principles (\u201cGAAP\u201d). Management evaluates and makes operating decisions using various performance measures. In addition to Omnicell\u2019s GAAP results, we also consider non-GAAP revenues, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP income from operations, non-GAAP operating margin, non-GAAP net income, non-GAAP net income per diluted share, non-GAAP diluted shares, non-GAAP EBITDA, non-GAAP EBITDA margin, and non-GAAP free cash flow. These non-GAAP results and metrics should not be considered as an alternative to revenues, gross profit, operating expenses, income from operations, net income, net income per diluted share, diluted shares, net cash provided by operating activities, or any other performance measure derived in accordance with GAAP. We present these non-GAAP results and metrics because management considers them to be important supplemental measures of Omnicell\u2019s performance and refers to such measures when analyzing Omnicell\u2019s strategy and operations.\n<\/p>\n<p>\nOur non-GAAP revenues, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP income from operations, non-GAAP operating margin, non-GAAP net income, non-GAAP net income per diluted share, non-GAAP EBITDA, and non-GAAP EBITDA margin are exclusive of certain items to facilitate management\u2019s review of the comparability of Omnicell\u2019s core operating results on a period-to-period basis because such items are not related to Omnicell\u2019s ongoing core operating results as viewed by management. We define our \u201ccore operating results\u201d as those revenues recorded in a particular period and the expenses incurred within such period that directly drive operating income in such period. Management uses these non-GAAP financial measures in making operating decisions because, in addition to meaningful supplemental information regarding operating performance, the measures give us a better understanding of how we believe we should invest in research and development, fund infrastructure growth, and evaluate the effectiveness of marketing strategies. In calculating the above non-GAAP results: non-GAAP revenues excludes from its GAAP equivalent item a) below; non-GAAP gross profit and non-GAAP gross margin exclude from their GAAP equivalents items a), b), c), f), and g) below; non-GAAP operating expenses excludes from its GAAP equivalents items b), c), d), e), f), g), and j) below; non-GAAP income from operations and non-GAAP operating margin exclude from their GAAP equivalents items a), b), c), d), e), f), g), and j) below; and non-GAAP net income and non-GAAP net income per diluted share exclude from their GAAP equivalents items a) through k) below. Non-GAAP EBITDA is defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as excluding certain other non-GAAP adjustments. Non-GAAP EBITDA and non-GAAP EBITDA margin exclude from their GAAP equivalents items a), b), d), e), f), g), h), i), and j) below:\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\na)\n<\/p>\n<\/td>\n<td class=\"bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<i>Acquisition accounting impact related to deferred revenues<\/i>. In connection with the recent acquisition of FDS Amplicare, we recorded a fair value adjustment to acquired deferred revenues as part of the purchase accounting in accordance with GAAP. The adjustment represents revenues that would have been recognized in the normal course of business by FDS Amplicare if the acquisition had not occurred, but was not recognized due to GAAP purchase accounting requirements. The non-GAAP adjustment to our revenues is intended to include the full amounts of such revenues. We believe the adjustment to these revenues is useful as a measure of the ongoing performance of our business.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nb)\n<\/p>\n<\/td>\n<td class=\"bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<i>Share-based compensation expense.<\/i> We excluded from our non-GAAP results the expense related to equity-based compensation plans as it represents expenses that do not require cash settlement from Omnicell.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nc)\n<\/p>\n<\/td>\n<td class=\"bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<i>Amortization of acquired intangible assets.<\/i> We excluded from our non-GAAP results the intangible assets amortization expense resulting from our past acquisitions. These non-cash charges are not considered by management to reflect the core cash-generating performance of the business and therefore are excluded from our non-GAAP results.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nd)\n<\/p>\n<\/td>\n<td class=\"bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<i>Acquisition-related expenses.<\/i> We excluded from our non-GAAP results the expenses related to recent acquisitions, including amortization of representations and warranties insurance. These expenses are unrelated to our ongoing operations, vary in size and frequency, and are subject to significant fluctuations from period to period due to varying levels of acquisition activity. We believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of less acquisitive peer companies.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\ne)\n<\/p>\n<\/td>\n<td class=\"bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<i>Impairment and abandonment of operating lease right-of-use assets related to facilities. <\/i>We excluded from our non-GAAP results the impairment and abandonment of operating lease right-of-use assets incurred in connection with restructuring activities for optimization of certain leased facilities. These non-cash charges are not considered by management to reflect the core cash-generating performance of the business and therefore are excluded from our non-GAAP results.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nf)\n<\/p>\n<\/td>\n<td class=\"bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<i>Ransomware-related expenses, net of insurance recoveries.<\/i> We excluded from our non-GAAP results the net expenses related to the previously disclosed ransomware incident identified by the Company on May 4, 2022. Expenses include costs to investigate and remediate the ransomware incident, as well as legal and other professional services, and are presented net of expected insurance recoveries. These expenses are unrelated to our ongoing operations and would not have otherwise been incurred by us in the normal course of business. We believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\ng)\n<\/p>\n<\/td>\n<td class=\"bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<i>Severance-related expenses.<\/i> We excluded from our non-GAAP results the expenses related to restructuring events. These expenses are unrelated to our ongoing operations, vary in size and frequency, and are subject to significant fluctuations from period to period due to varying levels of restructuring activity. We believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nh)\n<\/p>\n<\/td>\n<td class=\"bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<i>Amortization of debt issuance costs.<\/i> Debt issuance costs represent costs associated with the issuance of term loan and revolving credit facilities, as well as the issuance of convertible senior notes. The costs include underwriting fees, original issue discount, ticking fees, and legal fees. These non-cash expenses are not considered by management to reflect the core cash-generating performance of the business and therefore are excluded from our non-GAAP results.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\ni)\n<\/p>\n<\/td>\n<td class=\"bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<i>Amortization of discount on convertible senior notes.<\/i> We excluded from our non-GAAP results the amortization of the imputed discount on our convertible senior notes. Under GAAP (prior to the adoption of Accounting Standards Update 2020-06, effective January 1, 2022), certain convertible debt instruments that may be settled in cash upon conversion were required to be bifurcated into separate liability and equity components in a manner that reflects the issuer\u2019s assumed non-convertible debt borrowing rate. For GAAP purposes, we were required to recognize the imputed interest expense on the difference between our assumed non-convertible debt borrowing rate and the coupon rate on our convertible senior notes. This non-cash expense is not considered by management to reflect the core cash-generating performance of the business and therefore is excluded from our non-GAAP results.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nj)\n<\/p>\n<\/td>\n<td class=\"bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<i>Certain litigation costs. <\/i>We excluded non-recurring charges and benefits, including litigation expenses and settlements, related to litigation matters that are outside of the ordinary course of our business or that are not representative of those that we historically have incurred. These expenses are unrelated to our ongoing operations and we do not expect them to occur in the ordinary course of business. We believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nk)\n<\/p>\n<\/td>\n<td class=\"bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<i>Tax impact of IP restructuring. <\/i>We excluded from our non-GAAP results the tax impact related to the release of a net uncertain tax benefit as a result of effective settlement with the tax authorities related to prior IP restructuring. This impact is unrelated to our ongoing operations, and we do not expect it to occur in the ordinary course of business. We believe that excluding this impact provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies.\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\nManagement adjusts for the above items because management believes that, in general, these items possess one or more of the following characteristics: their magnitude and timing is largely outside of Omnicell\u2019s control; they are unrelated to the ongoing operation of the business in the ordinary course; they are unusual and we do not expect them to occur in the ordinary course of business; or they are non-operational or non-cash expenses involving stock compensation plans or other items.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nKathleen Nemeth<br \/>\n<br \/>Senior Vice President, Investor Relations<br \/>\n<br \/>650-435-3318<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#108;&#x74;&#111;&#x3a;K&#97;&#x74;h&#x6c;&#x65;&#101;&#x6e;&#46;&#78;&#x65;m&#x65;&#x74;&#104;&#x40;O&#109;&#x6e;&#105;&#x63;e&#108;&#x6c;&#46;&#99;&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x4b;&#x61;&#x74;&#104;&#108;&#101;en&#x2e;&#x4e;&#x65;&#x6d;&#101;&#116;h&#64;&#x4f;&#x6d;&#x6e;&#x69;&#99;&#101;ll&#x2e;&#x63;&#x6f;&#x6d;<\/a>\n<\/p>\n<p> <a href=\"http:\/\/www.businesswire.com\/news\/home\/20221102005381\/en\/Omnicell-Announces-Financial-Results-for-Third-Quarter-2022\/?feedref=Zd8jjkgYuzBwDixoAdXmJgT1albrG1Eq4mAeVP392103_ypKzv-7ah0oHKWbnuHnevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxZM7XiMhduiSeKMTNDLRqI_doMC3CVAuyHo5cJ7XfDuvA==\"> Read full story here <\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>GAAP and non-GAAP revenues of $348 million GAAP net income per diluted share of $0.37 Non-GAAP net income per diluted share of $1.00 SANTA CLARA, Calif.&#8211;(BUSINESS WIRE)&#8211;Omnicell, Inc. (NASDAQ:OMCL) (\u201cOmnicell,\u201d \u201cwe,\u201d \u201cour,\u201d \u201cus,\u201d \u201cmanagement,\u201d or the \u201cCompany\u201d), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/omnicell-announces-financial-results-for-third-quarter-2022\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50375","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Omnicell Announces Financial Results for Third Quarter 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/omnicell-announces-financial-results-for-third-quarter-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Omnicell Announces Financial Results for Third Quarter 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"GAAP and non-GAAP revenues of $348 million GAAP net income per diluted share of $0.37 Non-GAAP net income per diluted share of $1.00 SANTA CLARA, Calif.&#8211;(BUSINESS WIRE)&#8211;Omnicell, Inc. (NASDAQ:OMCL) (\u201cOmnicell,\u201d \u201cwe,\u201d \u201cour,\u201d \u201cus,\u201d \u201cmanagement,\u201d or the \u201cCompany\u201d), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/omnicell-announces-financial-results-for-third-quarter-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-02T12:02:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221102005381\/en\/770780\/21\/01_omnicell_lockup_horizontal_green_rgb.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"17 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omnicell-announces-financial-results-for-third-quarter-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omnicell-announces-financial-results-for-third-quarter-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Omnicell Announces Financial Results for Third Quarter 2022\",\"datePublished\":\"2022-11-02T12:02:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omnicell-announces-financial-results-for-third-quarter-2022\\\/\"},\"wordCount\":3364,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omnicell-announces-financial-results-for-third-quarter-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221102005381\\\/en\\\/770780\\\/21\\\/01_omnicell_lockup_horizontal_green_rgb.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omnicell-announces-financial-results-for-third-quarter-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omnicell-announces-financial-results-for-third-quarter-2022\\\/\",\"name\":\"Omnicell Announces Financial Results for Third Quarter 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omnicell-announces-financial-results-for-third-quarter-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omnicell-announces-financial-results-for-third-quarter-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221102005381\\\/en\\\/770780\\\/21\\\/01_omnicell_lockup_horizontal_green_rgb.jpg\",\"datePublished\":\"2022-11-02T12:02:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omnicell-announces-financial-results-for-third-quarter-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omnicell-announces-financial-results-for-third-quarter-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omnicell-announces-financial-results-for-third-quarter-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221102005381\\\/en\\\/770780\\\/21\\\/01_omnicell_lockup_horizontal_green_rgb.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221102005381\\\/en\\\/770780\\\/21\\\/01_omnicell_lockup_horizontal_green_rgb.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omnicell-announces-financial-results-for-third-quarter-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Omnicell Announces Financial Results for Third Quarter 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Omnicell Announces Financial Results for Third Quarter 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/omnicell-announces-financial-results-for-third-quarter-2022\/","og_locale":"en_US","og_type":"article","og_title":"Omnicell Announces Financial Results for Third Quarter 2022 - Pharma Trend","og_description":"GAAP and non-GAAP revenues of $348 million GAAP net income per diluted share of $0.37 Non-GAAP net income per diluted share of $1.00 SANTA CLARA, Calif.&#8211;(BUSINESS WIRE)&#8211;Omnicell, Inc. (NASDAQ:OMCL) (\u201cOmnicell,\u201d \u201cwe,\u201d \u201cour,\u201d \u201cus,\u201d \u201cmanagement,\u201d or the \u201cCompany\u201d), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/omnicell-announces-financial-results-for-third-quarter-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-02T12:02:32+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221102005381\/en\/770780\/21\/01_omnicell_lockup_horizontal_green_rgb.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"17 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/omnicell-announces-financial-results-for-third-quarter-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/omnicell-announces-financial-results-for-third-quarter-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Omnicell Announces Financial Results for Third Quarter 2022","datePublished":"2022-11-02T12:02:32+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/omnicell-announces-financial-results-for-third-quarter-2022\/"},"wordCount":3364,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/omnicell-announces-financial-results-for-third-quarter-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221102005381\/en\/770780\/21\/01_omnicell_lockup_horizontal_green_rgb.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/omnicell-announces-financial-results-for-third-quarter-2022\/","url":"https:\/\/pharma-trend.com\/en\/omnicell-announces-financial-results-for-third-quarter-2022\/","name":"Omnicell Announces Financial Results for Third Quarter 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/omnicell-announces-financial-results-for-third-quarter-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/omnicell-announces-financial-results-for-third-quarter-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221102005381\/en\/770780\/21\/01_omnicell_lockup_horizontal_green_rgb.jpg","datePublished":"2022-11-02T12:02:32+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/omnicell-announces-financial-results-for-third-quarter-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/omnicell-announces-financial-results-for-third-quarter-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/omnicell-announces-financial-results-for-third-quarter-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221102005381\/en\/770780\/21\/01_omnicell_lockup_horizontal_green_rgb.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221102005381\/en\/770780\/21\/01_omnicell_lockup_horizontal_green_rgb.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/omnicell-announces-financial-results-for-third-quarter-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Omnicell Announces Financial Results for Third Quarter 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50375","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50375"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50375\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50375"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50375"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50375"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}